The US Food and Drug Administration’s advisory committee briefing documents for Arbor Pharmaceuticals, LLC’s attentive deficit hyperactivity disorder stimulant show the agency may be losing enthusiasm for abuse deterrent drug formulations following little real-world data on proven public health successes and some new risks with the category of medicines in the opioid space.
Arbor is seeking approval of AR19, immediate release amphetamine sulfate oral capsules for ADHD, under the 505(b)(2) pathway. The company...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?